glp 1 based drugs Patients' Use GLP-1 for Weight Loss, Benefit Gains This gentle Discovery of GLP-1–Based Drugs for

reported in a propensity score-matched population-based cohort analysis that GLP-1 receptor agonist use in patients with MASLD and type 2 diabetes was associated with a lower risk of HCC (aHR: 0.55, 95%CI: 0.44-0.69) and all-cause mortality (aHR: 0.62, 95%CI: 0.55-0.71) [59]

Tirzepatide is the first dual agonist which has been approved for chronic weight management, but numerous other dual and/or triple agonists (cagrisema, retatrutide, mazdutide and survodutide) are also in phase 3 trials as potential treatments for obesity and its metabolic complications

In 2023, Humphrey and Lawrence emphasized the importance for plastic surgeons to recognize these potential effects, counsel patients before initiating therapy, and consider both surgical and non-surgical interventions to mitigate facial volume loss, sagging, and premature aging [86]

Need Help

Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study

Medicare does not cover weight loss medications, though some Medicare Advantage and Medigap plans do